The Role of Lymph Node Dissection in Renal Cell Carcinoma

The Pendulum Swings Back

Vitaly Margulis, Christopher G. Wood

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The incidence of regional lymph node metastases in patients with renal cell carcinoma ranges from 13% to over 30%, and portends a poor prognosis in both locally advanced and metastatic settings. Patients with small, organ confined tumors are at low risk for regional lymph node metastases and lymph node dissection can be omitted in these patients. In contrast, patients with clinical evidence of regional lymph node metastases may derive therapeutic benefit from aggressive removal of all affected lymph nodes within the retroperitoneum. Patients with locally advanced primary tumors but no clinical evidence of lymphadenopathy can be selectively targeted for aggressive lymph node dissection as an adjunct to radical nephrectomy, based on their individual risk of harboring micrometastatic lymph node disease. Several predictive tools have been developed for prediction of occult retroperitoneal nodal metastases. Although early identification of micrometastatic nodal disease in this group of patients has not conclusively been shown to improve survival, accurate pathologic nodal staging allows for early implementation of adjuvant systemic therapies in these high-risk patients. No formal guidelines exist regarding the extent and boundaries of lymph node dissection at the time of radical nephrectomy; however, overwhelming evidence suggests that the staging accuracy of lymph node dissection can be markedly improved if extended template dissections, rather than limited node sampling, is implemented.

Original languageEnglish (US)
Pages (from-to)308-314
Number of pages7
JournalCancer Journal
Volume14
Issue number5
StatePublished - Sep 2008

Fingerprint

Lymph Node Excision
Renal Cell Carcinoma
Lymph Nodes
Neoplasm Metastasis
Nephrectomy
Dissection
Neoplasms
Guidelines
Survival
Incidence
Therapeutics

Keywords

  • Lymph node dissection
  • Oncologic outcomes
  • Renal cell carcinoma
  • Staging

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The Role of Lymph Node Dissection in Renal Cell Carcinoma : The Pendulum Swings Back. / Margulis, Vitaly; Wood, Christopher G.

In: Cancer Journal, Vol. 14, No. 5, 09.2008, p. 308-314.

Research output: Contribution to journalArticle

@article{fbbd008a24ee41fe8398cde75f26c275,
title = "The Role of Lymph Node Dissection in Renal Cell Carcinoma: The Pendulum Swings Back",
abstract = "The incidence of regional lymph node metastases in patients with renal cell carcinoma ranges from 13{\%} to over 30{\%}, and portends a poor prognosis in both locally advanced and metastatic settings. Patients with small, organ confined tumors are at low risk for regional lymph node metastases and lymph node dissection can be omitted in these patients. In contrast, patients with clinical evidence of regional lymph node metastases may derive therapeutic benefit from aggressive removal of all affected lymph nodes within the retroperitoneum. Patients with locally advanced primary tumors but no clinical evidence of lymphadenopathy can be selectively targeted for aggressive lymph node dissection as an adjunct to radical nephrectomy, based on their individual risk of harboring micrometastatic lymph node disease. Several predictive tools have been developed for prediction of occult retroperitoneal nodal metastases. Although early identification of micrometastatic nodal disease in this group of patients has not conclusively been shown to improve survival, accurate pathologic nodal staging allows for early implementation of adjuvant systemic therapies in these high-risk patients. No formal guidelines exist regarding the extent and boundaries of lymph node dissection at the time of radical nephrectomy; however, overwhelming evidence suggests that the staging accuracy of lymph node dissection can be markedly improved if extended template dissections, rather than limited node sampling, is implemented.",
keywords = "Lymph node dissection, Oncologic outcomes, Renal cell carcinoma, Staging",
author = "Vitaly Margulis and Wood, {Christopher G.}",
year = "2008",
month = "9",
language = "English (US)",
volume = "14",
pages = "308--314",
journal = "Cancer Journal (United States)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The Role of Lymph Node Dissection in Renal Cell Carcinoma

T2 - The Pendulum Swings Back

AU - Margulis, Vitaly

AU - Wood, Christopher G.

PY - 2008/9

Y1 - 2008/9

N2 - The incidence of regional lymph node metastases in patients with renal cell carcinoma ranges from 13% to over 30%, and portends a poor prognosis in both locally advanced and metastatic settings. Patients with small, organ confined tumors are at low risk for regional lymph node metastases and lymph node dissection can be omitted in these patients. In contrast, patients with clinical evidence of regional lymph node metastases may derive therapeutic benefit from aggressive removal of all affected lymph nodes within the retroperitoneum. Patients with locally advanced primary tumors but no clinical evidence of lymphadenopathy can be selectively targeted for aggressive lymph node dissection as an adjunct to radical nephrectomy, based on their individual risk of harboring micrometastatic lymph node disease. Several predictive tools have been developed for prediction of occult retroperitoneal nodal metastases. Although early identification of micrometastatic nodal disease in this group of patients has not conclusively been shown to improve survival, accurate pathologic nodal staging allows for early implementation of adjuvant systemic therapies in these high-risk patients. No formal guidelines exist regarding the extent and boundaries of lymph node dissection at the time of radical nephrectomy; however, overwhelming evidence suggests that the staging accuracy of lymph node dissection can be markedly improved if extended template dissections, rather than limited node sampling, is implemented.

AB - The incidence of regional lymph node metastases in patients with renal cell carcinoma ranges from 13% to over 30%, and portends a poor prognosis in both locally advanced and metastatic settings. Patients with small, organ confined tumors are at low risk for regional lymph node metastases and lymph node dissection can be omitted in these patients. In contrast, patients with clinical evidence of regional lymph node metastases may derive therapeutic benefit from aggressive removal of all affected lymph nodes within the retroperitoneum. Patients with locally advanced primary tumors but no clinical evidence of lymphadenopathy can be selectively targeted for aggressive lymph node dissection as an adjunct to radical nephrectomy, based on their individual risk of harboring micrometastatic lymph node disease. Several predictive tools have been developed for prediction of occult retroperitoneal nodal metastases. Although early identification of micrometastatic nodal disease in this group of patients has not conclusively been shown to improve survival, accurate pathologic nodal staging allows for early implementation of adjuvant systemic therapies in these high-risk patients. No formal guidelines exist regarding the extent and boundaries of lymph node dissection at the time of radical nephrectomy; however, overwhelming evidence suggests that the staging accuracy of lymph node dissection can be markedly improved if extended template dissections, rather than limited node sampling, is implemented.

KW - Lymph node dissection

KW - Oncologic outcomes

KW - Renal cell carcinoma

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=55349093630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55349093630&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 308

EP - 314

JO - Cancer Journal (United States)

JF - Cancer Journal (United States)

SN - 1528-9117

IS - 5

ER -